1 / 25

VTE

VTE. V enous T hrombo E mbolism. VTE – aims of this module. To define the terms associated with VTE and offer maximum care to treat patients. To enable patients to have greater understanding of their risks, and how to prevent venous thromboembolism. VTE – What does this include?.

sven
Télécharger la présentation

VTE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VTE Venous ThromboEmbolism

  2. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To enable patients to have greater understanding of their risks, and how to prevent venous thromboembolism.

  3. VTE – What does this include? • Deep venous thrombosis (DVT) • Below knee (distal) • Above knee (proximal) • Atypical (eg arm) • Pulmonary embolism (PE) • Cerebral venous thrombosis

  4. Migration PE Embolus Thrombus VTE - deep vein thrombosis (DVT) & pulmonary embolism (PE) DVT

  5. VTE – Why does it happen? (Virchow’s Triad) Circulatory Stasis. (sluggish flow in the veins) Endothelial injury to veins. (due to trauma or inflammatory processes) Hypercoagulable state. (inherited or acquired pro-coagulant factors in the circulation)

  6. VTE – national context VTE is a major cause of morbidity and mortality in the UK VTE deaths are 5 times more than total deaths from Hospital Acquired Infection, Ca Breast, RTA and Acquired Immune Deficiency syndrome. 60,000 die per year from VTE. 25,000 of these are hospital patients Cost to NHS is £650 million

  7. VTE – acute consequences Acute VTE symptoms in the patient Painful, swollen leg Acute breathlessness Incapacity or sudden death Time & money spent on investigation & treatment of a potentially avoidable condition

  8. VTE – chronic consequences • Chronic VTE symptoms in the patient (25%) • Chronically painful, swollen leg • Leg ulcers & skin changes • Chronic breathlessness • Pulmonary hypertension • High risk of recurrence & therefore lifelong treatment with warfarin

  9. VTE - Who is at risk? Most patients admitted to hospital Particularly where there is; Immobility. Dehydration. Obesity Advanced age Acute & Chronic illness Surgical intervention

  10. VTE – Why risk assess? DocumentedRisk Assessment is vital as … It alerts both the patient & healthcare team to VTE risk & triggers practical VTE prevention measures (eg hydration, mobilization) Chemical +/- mechanical prophylaxis is highly effective at preventing VTE in high risk patients It is a DoH requirement

  11. VTE – What is the risk? • Without thromboprophylaxis VTE may develop in: • Up to 50% medical patients • Up to 40% orthopaedic patients • Up to 20% surgical patients • Only ½ hospital patients at risk of VTE in the UK are getting targetted prophylaxis

  12. VTE – we forget because although the risk is high it is not immediate Mean time to develop a VTE after elective hip surgery? 22 days. Mean time to develop a VTE after elective knee surgery? 10 days

  13. VTE – how to scale risk • Low risk (eg. young, mobile patient) • High risk (eg. Immobile with any risk factor) • Very high risk (history of previous VTE)

  14. What to do about VTE risk at SFT Is the patient immobile with at least 1 risk factor for VTE? YES NO Low risk No specific action High risk Is LMWH contraindicated? YES NO Very High = Both Prescribe TEDS Prescribe LMWH

  15. VTE – practical prevention Adequate hydration. Mobilisation as soon as possible Regular leg exercises Good positioning / posture / avoid hypothermia

  16. VTE – chemical prevention in patients at high risk Low Molecular Weight Heparin (LMWH) Dalteparin 5000iu od @ 18:00 Oral Anticoagulant THR or TKR for 5 weeks or 2 weeks Rivaroxaban 10mg od @ 18:00

  17. VTE – LMWH contraindications • Dalteparin is absolutely contraindicated in: • Patients at high risk of a serious / life threatening bleed • Major inherited bleeding disorders • Previous Heparin-induced thrombocytopenia • Other contraindications are relative (ie. balance of risk / benefit

  18. VTE – mechanical prevention • Mechanical compression devices (eg. Sequential compression devices - SCDs) must be used in theatre & can be carried on on the ward provided they are not off for >3hrs • Antiembolic stockings (eg. TEDs) should be used in High risk patients who cannot have chemical prevention or as an additional measure for patients who have previously damaged leg veins (eg DVT)

  19. VTE – contraindications to antiembolic stockings • Leg ulcers, peripheral vascular disease, peripheral neuropathy, lymphoedema • *** Badly fitted / applied stockings in patients with poor peripheral circulation can result in leg amputation

  20. VTE - the (haemo)dynamic balancerisk must be regularly re-assessed – a bleed will physiologically trigger clot formation BLEED CLOT

  21. Document VTE risk assessment here

  22. Prescribe VTE prophylaxis inside the drug chart

  23. VTE - tell your patient about their risk • Verbally • Information leaflet • DVD / Video available on request

  24. VTE – more information? ICID – “Thromboprophylaxis” DOH electronic learning tool http://e-lfh.org.uk/projects/vte/launch/ tamara.everington@salisbury.nhs.ukSue.snoxall@salisbury.nhs.uk

  25. VTE - Help prevent clots! By kind permission of Richard Curtis and Tony Robinson

More Related